-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, LY589oP012tR/Ich+qnGcbMMpyVP+uDaQVfdYr5oRU0wrwM3yPerBPCm8GkYVfuc HjrMvxKA9HZ/K6hlUn6U7A== 0001454982-10-000081.txt : 20100609 0001454982-10-000081.hdr.sgml : 20100609 20100609170157 ACCESSION NUMBER: 0001454982-10-000081 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20100601 FILED AS OF DATE: 20100609 DATE AS OF CHANGE: 20100609 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Weyer Christian CENTRAL INDEX KEY: 0001493811 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19700 FILM NUMBER: 10887719 MAIL ADDRESS: STREET 1: 9360 TOWNE CENTRE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMYLIN PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000881464 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330266089 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9360 TOWNE CENTRE DR STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 6195522200 MAIL ADDRESS: STREET 1: 9360 TOWNE CENTRE DR STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 3 1 edgardoc.xml PRIMARY DOCUMENT X0203 3 2010-06-01 0 0000881464 AMYLIN PHARMACEUTICALS INC AMLN 0001493811 Weyer Christian 9360 TOWNE CENTRE DR SAN DIEGO CA 92121 0 1 0 0 Sr. VP Research & Development Common Stock 2326 D Common Stock 4815 I by ESOP Incentive Stock Option (right to buy) 5.73 2011-10-04 Common Stock 5300 D Incentive Stock Option (right to buy) 9.02 2016-03-04 Common Stock 6252 D Incentive Stock Option (right to buy) 10.94 2012-06-28 Common Stock 3375 D Incentive Stock Option (right to buy) 11.5625 2011-01-26 Common Stock 15000 D Incentive Stock Option (right to buy) 11.95 2012-08-02 Common Stock 4600 D Incentive Stock Option (right to buy) 16.54 2015-05-25 Common Stock 4132 D Incentive Stock Option (right to buy) 18.01 2017-02-02 Common Stock 7360 D Incentive Stock Option (right to buy) 18.85 2013-05-12 Common Stock 6820 D Incentive Stock Option (right to buy) 19.79 2014-08-31 Common Stock 3467 D Incentive Stock Option (right to buy) 22.6 2014-05-03 Common Stock 6182 D Incentive Stock Option (right to buy) 24.87 2015-03-04 Common Stock 3973 D Incentive Stock Option (right to buy) 36.9 2017-03-07 Common Stock 1484 D Incentive Stock Option (right to buy) 41.34 2016-05-16 Common Stock 3680 D Non-Qualified Stock Option (right to buy) 9.02 2016-03-04 Common Stock 13748 D Non-Qualified Stock Option (right to buy) 16.54 2015-05-25 Common Stock 10868 D Non-Qualified Stock Option (right to buy) 18.01 2017-02-02 Common Stock 19340 D Non-Qualified Stock Option (right to buy) 18.85 2013-05-12 Common Stock 2180 D Non-Qualified Stock Option (right to buy) 19.79 2014-08-31 Common Stock 6533 D Non-Qualified Stock Option (right to buy) 22.6 2014-05-03 Common Stock 2818 D Non-Qualified Stock Option (right to buy) 24.87 2015-03-04 Common Stock 16027 D Non-Qualified Stock Option (right to buy) 36.9 2017-03-07 Common Stock 12516 D Non-Qualified Stock Option (right to buy) 41.34 2016-05-16 Common Stock 14320 D Includes 412 shares acquired pursuant to the Company's 401(k) plan which fully vested four years from the date of the reporting person's participation in the 401(k) plan. Represents shares acquired pursuant to the Company's ESOP. These shares fully vest four years from the date of the reporting person's participation in the ESOP in four equal annual installments and are generally distributed upon termination of employment. 25% of shares vest one year from date of grant and the remainder vest monthly over the next three years becoming fully vested four years from date of grant. By: /s/James R. Oehler, Attorney-in-Fact For: Christian Weyer 2010-06-09 EX-24 2 weyerpoa.htm EDGAR SUPPORTING DOCUMENT POWER OF ATTORNEY Known all by these presents, that the undersigned hereby authorizes Daniel M. Bradbury, Mark G. Foletta, Harry J. Leonhardt, Darin Lippoldt, Marcea Bland Lloyd, Lloyd A. Rowland or James R. Oehler to execute for and on behalf of the undersigned, in the undersigned's capacity as an executive officer of Amylin Pharmaceuticals, Inc. (the "Company"), Forms 3, 4 and 5 of any Amendments thereto, and cause such form(s) to be filed with the Securities and Exchange Commission pursuant to Section 16(a) of the Securities Exchange Act of 1934, relating to the undersigned's beneficial ownership of securities in the Company. The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or substitute or substitutes of such attorney-in-fact, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of, and transactions in, securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed this 1st day of June, 2010. /s/Christian Weyer Christian Weyer -----END PRIVACY-ENHANCED MESSAGE-----